Live feed
·
PRReleasevia Quantisnow
Inhibrx Biosciences Inc. logo

Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

ByQuantisnow·Wall Street's wire, on your screen.
INBX· Inhibrx Biosciences Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track INBX (Inhibrx Biosciences Inc.) and more on Quantisnow.